Literature DB >> 16983337

MUC1 is a novel regulator of ErbB1 receptor trafficking.

M R Pochampalli1, R M el Bejjani, J A Schroeder.   

Abstract

ErbB receptors are key regulators of cell survival and growth in normal and transformed tissues. The oncogenic glycoprotein MUC1 is a binding partner and substrate for erbB1 and MUC1 expression can potentiate erbB-dependent signal transduction. After receptor activation, erbB1 is typically downregulated via an endocytic pathway that results in receptor degradation or recycling. We report here that MUC1 expression inhibits the degradation of ligand-activated erbB1. Through the use of both RNAi-mediated knock down and overexpression constructs of MUC1, we show that MUC1 expression inhibits erbB1 degradation after ligand treatment in breast epithelial cells. This MUC1-mediated protection against erbB1 degradation can increase total cellular pools of erbB1 over time. Biotinylation of surface proteins demonstrates that cell-surface associated erbB1 receptor is protected by MUC1 against ligand-induced degradation, although this is accompanied by an increase in erbB1 internalization. The MUC1-mediated protection against degradation occurs with a decrease in EGF-stimulated ubiquitination of erbB1, and an increase in erbB1 recycling. These data indicate that MUC1 expression is a potent regulator of erbB1 receptor stability upon activation and may promote transformation through the inhibition of erbB1 degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983337     DOI: 10.1038/sj.onc.1209976

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 2.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

Review 3.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 4.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

Review 5.  MUC1 and MUC4: switching the emphasis from large to small.

Authors:  Huguette Albrecht; Kermit L Carraway
Journal:  Cancer Biother Radiopharm       Date:  2011-06       Impact factor: 3.099

6.  Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.

Authors:  Shuhei Tanida; Kaoru Akita; Akiko Ishida; Yugo Mori; Munetoyo Toda; Mizue Inoue; Mariko Ohta; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

Review 7.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

Review 8.  Anti-cancer therapies that utilize cell penetrating peptides.

Authors:  Benjamin G Bitler; Joyce A Schroeder
Journal:  Recent Pat Anticancer Drug Discov       Date:  2010-06       Impact factor: 4.169

9.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 10.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.